UK Markets close in 7 hrs 48 mins

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2700-0.0800 (-5.93%)
At close: 04:00PM EST
1.2700 0.00 (0.00%)
After hours: 06:43PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.3500
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's range1.2700 - 1.4100
52-week range1.2700 - 9.0800
Avg. volume1,019,542
Market cap157.187M
Beta (5Y monthly)1.05
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

    100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators BOSTON and LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data pu

  • Globe Newswire

    Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021

    BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences: Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 1:00 p.m. ET. The company is also taking part in a gene therapy development and regulatory panel discussion.Stifel 2021 Virtual Healthcare Conference on Novem

  • Globe Newswire

    Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates

    Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders Launch Activities for Libmeldy® Across Key European Countries, including Reimbursement Discussions, Progressing in Anticipation of Treating Commercial Patients Frank Thomas, President and Chief Operating Officer, to Step Down Following Transition in 2022; Search for a Chief Financial Officer Initiated C